L-Theanine Combination Therapy With Fluvoxamine in Moderate-To-Severe Obsessive–Compulsive Disorder: A Placebo-Controlled, Double-Blind, Randomized Trial

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):

Share this content! On (X network) By

L-Theanine Combination Therapy With Fluvoxamine in Moderate-To-Severe Obsessive–Compulsive Disorder: A Placebo-Controlled, Double-Blind, Randomized Trial Publisher Pubmed

Nematizadeh M¹ ; Ghorbanzadeh H¹ ; Moghaddam HS¹ ; Shalbafan M² ; Boroon M² ; Keshavarzakhlaghi AA² ; Akhondzadeh S¹

Show Affiliations

1. Psychiatric Research Center, Roozbeh Psychiatric Hospital, Tehran University of Medical Sciences, Tehran, Iran
2. Mental Health Research Center, Psychosocial Health Research Institute (PHRI), Department of Psychiatry, School of Medicine, Iran University of Medical Sciences, Tehran, Iran

Source: Psychiatry and Clinical Neurosciences Published:2023

Abstract

Aim: The main aim of this study was to investigate the additional effects of L-theanine, an amino acid in tea and an analog of glutamate with neuroprotective and anti-depressant properties, on obsessive–compulsive disorder (OCD) symptoms in combination with fluvoxamine. Methods: Patients from either sex aged between 18 and 60 years diagnosed with OCD, based on the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), who had a Yale-Brown Obsessive Compulsive Scale (Y-BOCS) score of more than 21 were enrolled in a double-blinded, parallel-group, placebo-controlled, clinical trial of 10 weeks to receive either L-theanine (100 mg twice daily) and fluvoxamine (100 mg daily initially followed by 200 mg daily after week 5) or placebo and fluvoxamine. The primary outcome of interest in this study was the Y-BOCS total score decrease from baseline. Results: From a total of 95 evaluated patients, 50 completed our study; 30 were randomly assigned to each group. Multivariate analysis (ANOVA) showed a significant effect of time (Figure presented.) treatment for L-theanine in obsession subscale (F = 5.51, P = 0.008) of the Y-BOCS score but not in the total and compulsion scores. Our results showed significantly more improvement in obsession subscale scores in L-theanine compared to placebo group (P = 0.007, Cohen's d = 0.82). Also, total Y-BOCS scores were lower in L-theanine compared to placebo group at week 5 (P = 0.039, Cohen's d = 0.60) and 10 (P = 0.008, Cohen's d = 0.80). However, there was no significant between-group differences in compulsion subscale scores. Complete response was also more frequent in the L-theanine group (P = 0.0001). Conclusion: Findings in this study suggest L-theanine as a relatively safe and effective adjuvant therapy for moderate to severe OCD. © 2023 The Authors. Psychiatry and Clinical Neurosciences © 2023 Japanese Society of Psychiatry and Neurology.

Related Docs

View other Related Docs

1. Minocycline Combination Therapy With Fluvoxamine in Moderate-To-Severe Obsessive–Compulsive Disorder: A Placebo-Controlled, Double-Blind, Randomized Trial, Psychiatry and Clinical Neurosciences (2016)

2. Amantadine As Adjuvant Therapy in the Treatment of Moderate to Severe Obsessive–Compulsive Disorder: A Double-Blind Randomized Trial With Placebo Control, Psychiatry and Clinical Neurosciences (2019)

3. Riluzole in Augmentation of Fluvoxamine for Moderate to Severe Obsessive–Compulsive Disorder: Randomized, Double-Blind, Placebo-Controlled Study, Psychiatry and Clinical Neurosciences (2016)

4. L-Carnosine As an Adjuvant to Fluvoxamine in Treatment of Obsessive Compulsive Disorder: A Randomized Double-Blind Study, Human Psychopharmacology (2017)

5. Glutamatergic Medications As Adjunctive Therapy for Moderate to Severe Obsessive-Compulsive Disorder in Adults: A Systematic Review and Meta-Analysis, BMC Pharmacology and Toxicology (2021)

6. Memantine Augmentation Improves Symptoms in Serotonin Reuptake Inhibitor-Refractory Obsessive-Compulsive Disorder: A Randomized Controlled Trial, Pharmacopsychiatry (2018)

7. N-Acetylcysteine Augmentation Therapy for Moderate-To-Severe Obsessive-Compulsive Disorder: Randomized, Double-Blind, Placebo-Controlled Trial, Journal of Clinical Pharmacy and Therapeutics (2016)

8. 5-Hydroxytryptophan As Adjuvant Therapy in Treatment of Moderate to Severe Obsessive-Compulsive Disorder: A Double-Blind Randomized Trial With Placebo Control, International Clinical Psychopharmacology (2020)

Experts (# of related papers)

View all Related Experts

Shahin Akhondzadeh Basti (25)

Mohammad Reza Mohammadi (4)

Other Related Docs

9. Fluvoxamine Combination Therapy With Tropisetron for Obsessive-Compulsive Disorder Patients: A Placebo-Controlled, Randomized Clinical Trial, Journal of Psychopharmacology (2019)

10. Comparison of Saffron and Fluvoxamine in the Treatment of Mild to Moderate Obsessive-Compulsive Disorder: A Double Blind, Randomized Clinical Trial, Iranian Journal of Psychiatry (2017)

11. Correlations Between Single Nucleotide Polymorphisms in Obsessive-Compulsive Disorder With the Clinical Features or Response to Therapy, Journal of Psychiatric Research (2023)

12. A Systematic Review and Meta-Analysis: Memantine Augmentation in Moderate to Severe Obsessive-Compulsive Disorder, Psychiatry Research (2019)

13. Repetitive Transcranial Magnetic Stimulation (Rtms) Improves Symptoms and Reduces Clinical Illness in Patients Suffering From Ocd - Results From a Single-Blind, Randomized Clinical Trial With Sham Cross-Over Condition, Journal of Psychiatric Research (2015)

14. L-Theanine Adjunct to Sertraline for Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial, Journal of Affective Disorders (2023)

15. Herbal Medicine in the Treatment of Obsessive Compulsive Disorder: A Review, Journal of Medicinal Plants (2019)

16. Does Oral Administration of Ketamine Accelerate Response to Treatment in Major Depressive Disorder? Results of a Double-Blind Controlled Trial, Journal of Affective Disorders (2018)

17. The Prevalence and Clinical Features of Amphetamine-Induced Obsessive Compulsive Disorder, Drug and Alcohol Dependence (2016)

18. Efficacy of N-Acetylcysteine Augmentation on Obsessive Compulsive Disorder: A Multicenter Randomized Double Blind Placebo Controlled Clinical Trial, Iranian Journal of Psychiatry (2017)

19. L-Carnosine Combination Therapy for Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial, Journal of Affective Disorders (2020)

20. Effect of Memantine Combination Therapy on Symptoms in Patients With Moderate-To-Severe Depressive Disorder: Randomized, Double-Blind, Placebo-Controlled Study, Journal of Clinical Pharmacy and Therapeutics (2017)

21. Reboxetine Combination Therapy With Fluoxetine in Moderate to Severe Obsessive-Compulsive Disorder: A Placebo-Controlled, Double-Blind, Randomized Trial, Clinical Neuropharmacology (2023)

22. Palmitoylethanolamide As Adjunctive Therapy in Major Depressive Disorder: A Double-Blind, Randomized and Placebo-Controlled Trial, Journal of Affective Disorders (2018)

23. Risperidone Combination Therapy With Propentofylline for Treatment of Irritability in Autism Spectrum Disorders: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial, Clinical Neuropharmacology (2019)

24. Simvastatin Versus Atorvastatin for Improving Mild to Moderate Depression in Post-Coronary Artery Bypass Graft Patients: A Double-Blind, Placebo-Controlled, Randomized Trial, Journal of Affective Disorders (2015)

25. Depression and Inflammation: Is There Any Role for Biomarkers?, Avicenna Journal of Medical Biotechnology (2019)

26. Cilostazol As an Adjunctive Treatment in Major Depressive Disorder: A Pilot Randomized, Double-Blind, and Placebo-Controlled Clinical Trial, Psychopharmacology (2022)

27. Riluzole for Treatment of Men With Methamphetamine Dependence: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial, Journal of Psychopharmacology (2019)

28. L-Carnosine As Adjunctive Therapy in Children and Adolescents With Attention-Deficit/Hyperactivity Disorder: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial, Journal of Child and Adolescent Psychopharmacology (2018)

29. Patients With Ocd Report Lower Quality of Life After Controlling for Expert-Rated Symptoms of Depression and Anxiety, Psychiatry Research (2018)

30. L-Carnosine As an Adjunctive Therapy to Risperidone in Children With Autistic Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial, Journal of Child and Adolescent Psychopharmacology (2018)

31. Validation for Persian Versions of “Desire for Drug Questionnaire” and “Obsessive Compulsive Drug Use Scale” in Heroin Dependents, Archives of Iranian Medicine (2016)

32. Riluzole Combination Therapy for Moderate-To-Severe Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial, Journal of Psychiatric Research (2016)

33. L-Theanine Adjunct to Risperidone in the Treatment of Chronic Schizophrenia Inpatients: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial, Psychopharmacology (2023)

34. Repetitive Transcranial Magnetic Stimulation Improved Symptoms of Obsessive-Compulsive Disorder, But Also Cognitive Performance: Results From a Randomized Clinical Trial With a Cross-Over Design and Sham Condition, Neuropsychobiology (2016)

35. Celecoxib As an Adjuvant to Fluvoxamine in Moderate to Severe Obsessive-Compulsive Disorder: A Double-Blind, Placebo-Controlled, Randomized Trial, Pharmacopsychiatry (2015)

36. The Efficacy of Aripiprazole Versus Risperidone As Augmentation Therapy in Treatment-Resistant Obsessive-Compulsive Disorder: A Double Blind Clinical Trial, Iranian Red Crescent Medical Journal (2018)

Style	Citing Format
MLA	Nematizadeh M, et al.. "L-Theanine Combination Therapy With Fluvoxamine in Moderate-To-Severe Obsessive–Compulsive Disorder: A Placebo-Controlled, Double-Blind, Randomized Trial." Psychiatry and Clinical Neurosciences, vol. 77, no. 9, 2023, pp. 478-485.
APA	Nematizadeh M, Ghorbanzadeh H, Moghaddam HS, Shalbafan M, Boroon M, Keshavarzakhlaghi AA, Akhondzadeh S (2023). L-Theanine Combination Therapy With Fluvoxamine in Moderate-To-Severe Obsessive–Compulsive Disorder: A Placebo-Controlled, Double-Blind, Randomized Trial. Psychiatry and Clinical Neurosciences, 77(9), 478-485.
Chicago	Nematizadeh M, Ghorbanzadeh H, Moghaddam HS, Shalbafan M, Boroon M, Keshavarzakhlaghi AA, Akhondzadeh S. "L-Theanine Combination Therapy With Fluvoxamine in Moderate-To-Severe Obsessive–Compulsive Disorder: A Placebo-Controlled, Double-Blind, Randomized Trial." Psychiatry and Clinical Neurosciences 77, no. 9 (2023): 478-485.
Harvard	Nematizadeh M et al. (2023) 'L-Theanine Combination Therapy With Fluvoxamine in Moderate-To-Severe Obsessive–Compulsive Disorder: A Placebo-Controlled, Double-Blind, Randomized Trial', Psychiatry and Clinical Neurosciences, 77(9), pp. 478-485.
Vancouver	Nematizadeh M, Ghorbanzadeh H, Moghaddam HS, Shalbafan M, Boroon M, Keshavarzakhlaghi AA, et al.. L-Theanine Combination Therapy With Fluvoxamine in Moderate-To-Severe Obsessive–Compulsive Disorder: A Placebo-Controlled, Double-Blind, Randomized Trial. Psychiatry and Clinical Neurosciences. 2023;77(9):478-485.
BibTex	@article{ author = {Nematizadeh M and Ghorbanzadeh H and Moghaddam HS and Shalbafan M and Boroon M and Keshavarzakhlaghi AA and Akhondzadeh S}, title = {L-Theanine Combination Therapy With Fluvoxamine in Moderate-To-Severe Obsessive–Compulsive Disorder: A Placebo-Controlled, Double-Blind, Randomized Trial}, journal = {Psychiatry and Clinical Neurosciences}, volume = {77}, number = {9}, pages = {478-485}, year = {2023} }
RIS	TY - JOUR AU - Nematizadeh M AU - Ghorbanzadeh H AU - Moghaddam HS AU - Shalbafan M AU - Boroon M AU - Keshavarzakhlaghi AA AU - Akhondzadeh S TI - L-Theanine Combination Therapy With Fluvoxamine in Moderate-To-Severe Obsessive–Compulsive Disorder: A Placebo-Controlled, Double-Blind, Randomized Trial JO - Psychiatry and Clinical Neurosciences VL - 77 IS - 9 SP - 478 EP - 485 PY - 2023 ER -

Science Communicator Platform

Authors

Authors Affiliations

Abstract